









Markets
/
Stocks
/
nasdaq-biib
/

Biogen Inc

BIIB

189.180USD

+5.240+2.85%

Close 03/25, 16:00（ET）Quotes delayed by 15 min

45.32BMarket Cap

21.44P/E TTM



Biogen Inc

189.180

+5.240+2.85%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Biogen Inc

Currency: USD Updated: 2026-03-25

Key Insights

Biogen Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 24 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 206.49.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Biogen Inc's Score

Industry at a Glance

Industry Ranking

24 / 157

Overall Ranking

87 / 4547

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Biogen Inc Highlights

StrengthsRisks

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Fairly Valued

The company’s latest PE is 21.44, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 139.65M shares, increasing 0.10% quarter-over-quarter.

Held by ETHSX

Star Investor ETHSX holds 15.08K shares of this stock.

Analyst Rating

Based on 37 analysts

Buy

Current Rating

206.495

Target Price

+12.45%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-25

The current financial score of Biogen Inc is 7.12, ranking 123 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 2.28B, representing a year-over-year decrease of 7.14%, while its net profit experienced a year-over-year decrease of 118.34%.

Score

Industry at a Glance

Previous score

7.12

Change



Financials

7.07

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.65

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.47

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.41

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Biogen Inc's Company Valuation

Currency: USD Updated: 2026-03-25

The current valuation score of Biogen Inc is 7.76, ranking 47 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is 21.44, which is 55.64% below the recent high of 33.36 and 100.00% above the recent low of 0.00.

Score

Industry at a Glance

Previous score

7.76

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 24/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-25

The current earnings forecast score of Biogen Inc is 7.14, ranking 113 out of 157 in the Pharmaceuticals industry. The average price target is 171.00, with a high of 260.00 and a low of 130.00.

Score

Industry at a Glance

Previous score

7.14

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 37 analysts

Buy

Current Rating

206.495

Target Price

+12.45%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

AbbVie Inc

ABBV

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-25

The current price momentum score of Biogen Inc is 8.40, ranking 25 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 194.67 and the support level at 182.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.50

Change

1.9

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.305

Sell

RSI(14)

54.606

Neutral

STOCH(KDJ)(9,3,3)

64.468

Buy

ATR(14)

4.715

Low Volatility

CCI(14)

90.916

Neutral

Williams %R

30.095

Buy

TRIX(12,20)

-0.118

Sell

StochRSI(14)

100.000

Overbought

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

184.326

Buy

MA10

183.894

Buy

MA20

186.043

Buy

MA50

184.258

Buy

MA100

178.204

Buy

MA200

157.674

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-25

The current institutional shareholding score of Biogen Inc is 10.00, ranking 1 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 97.81%, representing a quarter-over-quarter decrease of 0.75%. The largest institutional shareholder is The Vanguard, holding a total of 17.37M shares, representing 11.83% of shares outstanding, with 2.25% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

17.21M

-0.01%

PRIMECAP Management Company

Star Investors

14.95M

-5.36%

BlackRock Institutional Trust Company, N.A.

8.21M

+0.24%

State Street Investment Management (US)

7.32M

-2.00%

Geode Capital Management, L.L.C.

4.07M

+3.84%

Wellington Management Company, LLP

4.25M

-11.50%

Point72 Asset Management, L.P.

Star Investors

3.87M

+1.07%

Norges Bank Investment Management (NBIM)

2.26M

-2.62%

Risk Assessment

Currency: USD Updated: 2026-03-25

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Biogen Inc is 7.96, ranking 31 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.16. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.